vs
Side-by-side financial comparison of Kymera Therapeutics, Inc. (KYMR) and Maase Inc. (MAAS). Click either name above to swap in a different company.
Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $9.9M, roughly 1.2× Maase Inc.). Maase Inc. produced more free cash flow last quarter ($-18.3M vs $-60.6M).
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
KYMR vs MAAS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $9.9M |
| Net Profit | $-76.6M | — |
| Gross Margin | — | 78.7% |
| Operating Margin | -736.8% | -55.9% |
| Net Margin | -667.6% | — |
| Revenue YoY | -55.3% | — |
| Net Profit YoY | -82.1% | — |
| EPS (diluted) | $-0.95 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $11.5M | — | ||
| Q1 25 | $22.1M | — | ||
| Q4 24 | $7.4M | — | ||
| Q2 24 | $25.6M | — | ||
| Q1 24 | $10.3M | — | ||
| Q4 23 | $47.9M | — | ||
| Q2 23 | $16.5M | — | ||
| Q1 23 | $9.5M | — |
| Q2 25 | $-76.6M | — | ||
| Q1 25 | $-65.6M | — | ||
| Q4 24 | $-70.8M | — | ||
| Q2 24 | $-42.1M | — | ||
| Q1 24 | $-48.6M | — | ||
| Q4 23 | $-14.4M | — | ||
| Q2 23 | $-38.8M | — | ||
| Q1 23 | $-40.9M | — |
| Q2 25 | -736.8% | — | ||
| Q1 25 | -336.8% | — | ||
| Q4 24 | -1092.2% | — | ||
| Q2 24 | -198.5% | — | ||
| Q1 24 | -562.2% | — | ||
| Q4 23 | -40.3% | — | ||
| Q2 23 | -262.7% | — | ||
| Q1 23 | -478.8% | — |
| Q2 25 | -667.6% | — | ||
| Q1 25 | -296.7% | — | ||
| Q4 24 | -956.9% | — | ||
| Q2 24 | -164.0% | — | ||
| Q1 24 | -472.0% | — | ||
| Q4 23 | -30.0% | — | ||
| Q2 23 | -235.0% | — | ||
| Q1 23 | -432.4% | — |
| Q2 25 | $-0.95 | — | ||
| Q1 25 | $-0.82 | — | ||
| Q4 24 | $-0.89 | — | ||
| Q2 24 | $-0.58 | — | ||
| Q1 24 | $-0.69 | — | ||
| Q4 23 | $-0.25 | — | ||
| Q2 23 | $-0.67 | — | ||
| Q1 23 | $-0.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $335.8M | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $971.5M | $31.6M |
| Total Assets | $1.1B | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $335.8M | — | ||
| Q1 25 | $90.0M | — | ||
| Q4 24 | $120.3M | — | ||
| Q2 24 | $67.6M | — | ||
| Q1 24 | $93.5M | — | ||
| Q4 23 | $110.0M | — | ||
| Q2 23 | $52.4M | — | ||
| Q1 23 | $50.2M | — |
| Q2 25 | $971.5M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $835.6M | — | ||
| Q2 24 | $684.9M | — | ||
| Q1 24 | $711.2M | — | ||
| Q4 23 | $395.0M | — | ||
| Q2 23 | $435.4M | — | ||
| Q1 23 | $462.0M | — |
| Q2 25 | $1.1B | — | ||
| Q1 25 | $918.3M | — | ||
| Q4 24 | $978.0M | — | ||
| Q2 24 | $826.0M | — | ||
| Q1 24 | $868.3M | — | ||
| Q4 23 | $575.8M | — | ||
| Q2 23 | $581.9M | — | ||
| Q1 23 | $613.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.9M | $-18.2M |
| Free Cash FlowOCF − Capex | $-60.6M | $-18.3M |
| FCF MarginFCF / Revenue | -527.9% | -184.4% |
| Capex IntensityCapex / Revenue | 6.1% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-250.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-59.9M | — | ||
| Q1 25 | $-79.2M | — | ||
| Q4 24 | $-61.8M | — | ||
| Q2 24 | $-42.9M | — | ||
| Q1 24 | $-39.6M | — | ||
| Q4 23 | $8.0M | — | ||
| Q2 23 | $-35.3M | — | ||
| Q1 23 | $-44.0M | — |
| Q2 25 | $-60.6M | — | ||
| Q1 25 | $-79.6M | — | ||
| Q4 24 | $-62.7M | — | ||
| Q2 24 | $-47.6M | — | ||
| Q1 24 | $-47.0M | — | ||
| Q4 23 | $-3.6M | — | ||
| Q2 23 | $-46.0M | — | ||
| Q1 23 | $-48.0M | — |
| Q2 25 | -527.9% | — | ||
| Q1 25 | -360.3% | — | ||
| Q4 24 | -848.3% | — | ||
| Q2 24 | -185.7% | — | ||
| Q1 24 | -456.8% | — | ||
| Q4 23 | -7.5% | — | ||
| Q2 23 | -278.7% | — | ||
| Q1 23 | -506.8% | — |
| Q2 25 | 6.1% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 12.7% | — | ||
| Q2 24 | 18.3% | — | ||
| Q1 24 | 72.0% | — | ||
| Q4 23 | 24.3% | — | ||
| Q2 23 | 65.2% | — | ||
| Q1 23 | 42.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KYMR
Segment breakdown not available.
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
